NG Bio
Europe, England, United Kingdom, London'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
Description
NG Bio is a therapeutic ventures that can change outcomes for patients with autoimmune and chronic inflammatory diseases.
Investor Profile
NG Bio has backed more than 2 startups, with 0 new investments in the last 12 months alone. The firm has led 2 rounds, about 100% of its total and boasts 0 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series Unknown, Seed rounds (top funding stages).
- Majority of deals are located in United Kingdom.
- Strong thematic focus on Biotechnology, Therapeutics.
Stage Focus
- Series Unknown (50%)
- Seed (50%)
Country Focus
- United Kingdom (100%)
Industry Focus
- Biotechnology
- Therapeutics
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
